 safeti pharmacokinet hydroxynaphthoquinon anti-pneumocysti carinii activ phase human immunodefici viru hiv men hydroxynaphthoquinon compound effect prevent treatment murin pneumocysti carinii pneumon phase cohort human immunodefici virus-infect men mg compound daili day sixth cohort mg time day day evalu clinic hematolog biochem studi pharmacokinet drug-rel advers effect maculopapular rash patient discontinu drug dosag mg follow pharmacokinet measur maximum plasma concentr micrograms/ml time plasma concentr area plasma concentration-tim curv steadi state h.micrograms/ml half-lif total plasma clearanc l/h compound offer new drug class carinii pneumonia